Clarivate Plc has signed an agreement to sell its Life Sciences and Healthcare business to an affiliate of Altaris, LLC for $600 million. The deal includes $500 million in cash at closing, $25 million in deferred payments, and a $75 million unsecured senior note. The sale is expected to close by the end of 2026, and it does not require shareholder approval.

View Full Filing (SEC EDGAR)

2026-07-06

No AI summary for this filing type

View Full Filing (SEC EDGAR)

View all Form 8-K filings

FAQ

Who are the top institutional investors holding Clarivate Plc (CLVT)?

Major stakeholders currently include Leonard Green & Partners, L.P. ($295.2M), Exor N.V. ($170.3M), Clarkston Capital Partners, LLC ($108.4M). Based on the latest 13F filings, there are a total of 254 tracked investment funds and institutions maintaining positions in CLVT.

What is the overall institutional sentiment toward CLVT recently?

Institutional sentiment appears Bearish (Net Selling). During the most recent reporting quarter, the stock experienced a net outflow of $351.3M, driven by 187 managers accumulating shares while 74 reduced their exposure.

Which institutions have been selling or reducing their CLVT positions?

In the latest period, 33 funds trimmed their holdings, and 41 managers completely exited their positions. The aggregate reported sell value was $496.0M.

Are there any notable investors adding CLVT to their portfolios?

Yes, buying activity remains notable. 77 institutions opened new positions in {ticker}, and 110 existing holders added to their shares. The total reported buy value for the quarter amounted to $587.4M.